Share Name Share Symbol Market Type Share ISIN Share Description
Synairgen Plc LSE:SNG London Ordinary Share GB00B0381Z20 ORD 1P
  Price Change % Change Share Price Shares Traded Last Trade
  -5.80 -3.48% 161.00 1,630,412 16:35:22
Bid Price Offer Price High Price Low Price Open Price
159.30 162.90 166.40 158.00 166.00
Industry Sector Turnover (m) Profit (m) EPS - Basic PE Ratio Market Cap (m)
Pharmaceuticals & Biotechnology -17.73 -9.46 322
Last Trade Time Trade Type Trade Size Trade Price Currency
17:08:01 O 2,120 161.008 GBX

Synairgen (SNG) Latest News (1)

More Synairgen News
Synairgen Investors    Synairgen Takeover Rumours

Synairgen (SNG) Discussions and Chat

Synairgen Forums and Chat

Date Time Title Posts
19/6/202101:55SNG Blip in the Matrix is due 44.44297
18/6/202123:09Synairgen - a potential cure for Covid 19?19,400
18/6/202122:06SNG001; a potential treatment for Covid 1947,837
17/6/202110:11Synairgen - no cure for gambling losers.521
14/6/202120:35Bullshit free zone180

Add a New Thread

Synairgen (SNG) Most Recent Trades

Trade Time Trade Price Trade Size Trade Value Trade Type
2021-06-18 16:08:03161.012,1203,413.37O
2021-06-18 15:58:29162.271,6182,625.53O
2021-06-18 15:35:22161.0023,42637,715.86UT
2021-06-18 15:29:58160.1012,49720,007.70O
2021-06-18 15:29:53162.5084136.50AT
View all Synairgen trades in real-time

Synairgen (SNG) Top Chat Posts

Synairgen Daily Update: Synairgen Plc is listed in the Pharmaceuticals & Biotechnology sector of the London Stock Exchange with ticker SNG. The last closing price for Synairgen was 166.80p.
Synairgen Plc has a 4 week average price of 100p and a 12 week average price of 95.40p.
The 1 year high share price is 259p while the 1 year low share price is currently 33.50p.
There are currently 199,914,402 shares in issue and the average daily traded volume is 3,038,550 shares. The market capitalisation of Synairgen Plc is £321,862,187.22.
festario: If, as I've heard, that SNG has moved from Phase 3 of Activ2, then this is the mega news we've been waiting for.This is surely an RNS for material development.The share price is reacting, so it would seem to be true.
thelongandtheshortandthetall: For newbies looking in, to get a flavour of SNG: Synairgen plc Full Year Results 12/05/2021 7:00am UK Regulatory (RNS & others) Synairgen (LSE:SNG) Historical Stock Chart From May 2021 to Jun 2021 Click Here for more Synairgen Charts. TIDMSNG RNS Number : 3453Y Synairgen plc 12 May 2021 Press release Synairgen plc ('Synairgen' or the 'Company') Preliminary results for the year ended 31 December 2020 - Significant progress continues towards a treatment for COVID-19 Southampton, UK - 12 May 2021: Synairgen plc (LSE: SNG), the respiratory company developing inhaled interferon beta (IFN-beta) for the treatment of severe viral lung infections, today announces its preliminary statement of audited results for the year ended 31 December 2020. Highlights (including post period-end) Operational -- Positive results from Synairgen's Phase II trial (SG016) of inhaled interferon beta-1a (SNG001) in 101 hospitalised COVID-19 patients reported in July 2020 - Further analyses announced in September 2020 and trial data published in The Lancet Respiratory Medicine in November 2020 -- SG016 trial expanded to include a further 120 COVID-19 patients in the home environment - Analysis of combined data from Hospital and Home Cohorts in April 2021 showed that patients with significant breathlessness are three times more likely to recover to "no limitation of activities" on the OSCI scale when receiving SNG001 compared to placebo (p=0.004) -- SNG001 awarded Fast Track designation with IND cleared by the US FDA in December -- International Phase III trial (SG018) of SNG001 in hospitalised COVID-19 patients initiated in December 2020 - First patient dosed in January 2021, initial trial results expected in H2 2021 -- SNG001 included in US NIH government-funded ACTIV-2 Phase II/III trial in COVID-19 outpatients in January 2021 and commenced patient dosing in February 2021 - Phase II evaluation will see the recruitment of up to 220 participants -- Investment in supply chain activities for SNG001 and the Aerogen aerosol delivery system have been made in preparation for launch -- Agreements signed with Akron Biotechnology for drug substance manufacture and Catalent Biologics for fill/finish -- Positive data from interim analysis of SNG001 trial in COPD patients supporting future progression of SNG001 for exacerbating COPD patients -- Patent applications made for use of inhaled interferon beta-1a to treat: - COVID-19 patients - Virus-induced exacerbations of COPD patients undergoing treatment with systemic corticosteroids Financial -- In October 2020, Synairgen raised GBP87.1 million (before expenses) in an equity issue to fund SG018 Phase III trial, SNG001 manufacturing, regulatory activities, and to strengthen balance sheet -- In March 2020, Synairgen raised GBP14.0 million (before expenses) in an equity issue to fund initial COVID-19 clinical trial activity -- The loss from operations for the year ended 31 December 2020 was GBP17.7 million (2019: GBP4.8 million), with research and development expenditure amounting to GBP15.5 million (2019: GBP3.5 million) - GBP12.0 million year-on-year increase on research and development expenditure attributable to COVID-19 activities -- Cash balances of GBP75.0 million at 31 December 2020 (31 December 2019: GBP2.5 million) Richard Marsden, CEO of Synairgen, said: "Synairgen has made exceptional progress over 2020, with our broad-spectrum antiviral taking centre stage as a possible treatment for COVID-19, supported by a growing body of clinical evidence. Our inhaled interferon beta candidate, SNG001, has now demonstrated in a number of robust placebo-controlled clinical trials that it has the potential to prevent patient deterioration and accelerate recovery. Alongside vaccines, access to treatments that are both virus and strain agnostic is critical. Our efforts are focused on making such treatments available to the public as swiftly as possible by advancing our late-stage clinical trials, seeking marketing authorisations and ensuring the manufacturing and commercial capabilities can be rapidly up-scaled to meet potential demand."
little minx: I sold all my SNG the other day and have a long with IG. Better to lose a few hundred than a few thousands.Today I don't understand the share price as the Indian variant takes hold and nobody really knows the efficacy of the vaccines in this respect.I feel sorry for SNG as our government obviously have a problem with its non association with Oxford which sounds so churlish but probably oh so true. I also feel sorry for the large number of people SNG could have assisted. Disgraceful.I have a figure I will buy at again but my other worry is the markets are in turmoil.
umatingytribe: Share slide looks to be easing. Something is/has gone on behind the scenes. What that is/was and what it means remains elusive. If the share price breaks down any further, I.m definitely taking it as a sign of a placing, although the share price seems to have bottomed. If a c19 therspy like Syns IB isnt perceived as vital, then I.m a Mackem.
mikro1: The share price has fallen because it is clear that we now all have to wait for the phase 3 results. If they are successful any holders will be well rewarded. As for the share price over the next 3-6 months - that could be volatile.
hazl: No they have already got out as l did a while ago! Look at the chart head and shoulders. Now l believe the share price ought to react more positively to the long covid worry and possibly getting closer to results. I am still supporting this share for humanity. If and when it is proven then the share price will reflect and ought to show success.
walkermike1: The whole market has lost confidence in SNG. The world has moved on, vaccine production has moved into overdrive and the natural conclusion is herd immunity. Yes, there will still be a requirement for products like SNG001, but it is no longer the panacea, which was really the catalyst for the share price spike up. Hey, if the share price dropped to 50p, many holders are still in the money.
hazl: SNG Has not 'missed the boat'. All virus companies are levelling off but SNG has been working up to securing a treatment for COPD for some years. These things take time. It could be argued that the virus expedited the whole process for Synairgen,thrusting it into the limelight with the rest of the candidates. If and when this gets processed and passed for the numerous respiratory conditions and shows that it aids sufferers, even after the dreadful virus has been quelled, then I expect to see SNG 's profile being raised and our share price in tandem. It is still a rocky road but I feel the end is in sight. Well done to the team!
gbh2: LOL, as if closing a advfn user's short is going to rock the SNG share price :))
mikro1: Nothing has been leaked. Just the normal case of an AIM share drifting down between news. The position remains the same - if the next RNS contains a successful result the share price will go up 3-5x. If it contains a failure the share price will go down by 50-80%. We all just have to wait. I have learnt from experience that PIs usually give up and sell out just before great news. I will wait and let the clinical trial determine the fate of my investment.
Synairgen share price data is direct from the London Stock Exchange
ADVFN Advertorial
Your Recent History
Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

P: V: D:20210619 04:36:31